Pendal Group’s BioTelemetry, Inc. BEAT Stock Holding History

Pendal Group’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-9,393	Closed	-$314K	–	519
2017 Q2	$314K	Buy	+9,393	New	+$280K	﹤0.01%	396

Other funds holding BEAT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pendal Group's BEAT Position: Q3 2017 in Review

Pendal Group sold out of BioTelemetry, Inc. (BEAT) in Q3 2017, closing a stake of 9,393 shares — an estimated $314K sold.

Pendal Group first reported a position in BEAT in Q2 2017 and held it in 1 quarter. The position peaked at $314K in Q2 2017. 211 funds tracked by Wall St. Rank hold BEAT as of Q3 2017.

Pendal Group reported no remaining BioTelemetry, Inc. position as of Q3 2017 after selling out during the quarter.
Pendal Group sold 9,393 BioTelemetry, Inc. shares in Q3 2017, an estimated $314K.
Pendal Group first reported a position in BioTelemetry, Inc. in Q2 2017 and held it in 1 quarter.
Pendal Group's BioTelemetry, Inc. position peaked at $314K in Q2 2017.
211 funds tracked by Wall St. Rank held BioTelemetry, Inc. as of Q3 2017.

Based on Pendal Group's 13F filing for Q3 2017, filed 1 Nov 2017.